A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5%
 minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
This is a randomized, multicenter, double-blind, vehicle-controlled, 2 arm study to evaluate
 the safety and efficacy of FMX103 topical foam containing 1.5% minocycline compared to
 vehicle, in the treatment of participants with moderate-to-severe facial papulopustular
 rosacea. Qualified participants will be randomized in a 2:1 ratio (active:vehicle) to receive
 1 of the following 2 treatments:

 -  FMX103 minocycline foam 1.5%

 -  Vehicle foam

 Participants will be assigned to 1 of 2 treatments according to the randomization schedule.
 Participants will apply (or have applied) the study drug topically once daily for 12 weeks as
 directed. Participants will be advised to use the study drug at approximately the same time
 each day. Both the Investigator and participant will be blinded to the study drug identity.
 Participants will return for visits at Weeks 1, 4, 6, 8, 10, and 12. Efficacy evaluations
 (inflammatory lesion counts and Investigator's Global Assessment [IGA] score) will be
 performed at Weeks 4, 8, and 12 during the study.

 Note: Originally the two studies FX2016-11 and FX2016-12 were combinedly presented in the
 protocol registration form under one NCT number (NCT03142451), and later separated since
 results were analyzed separately.
Inclusion Criteria:

 1. Moderate-to-severe rosacea (as per the IGA score) on the proposed facial treatment
 area consisting of:

 1. At least 15 and not more than 75 facial papules and pustules, excluding lesions
 involving the eyes and scalp;

 2. No more than 2 nodules on the face.

 2. Presence of or history of erythema and/or flushing on the face.

 Exclusion Criteria:

 1. Presence of any skin condition and/or Excessive facial hair, on the face that would
 interfere with the diagnosis or assessment of rosacea.

 2. Moderate or severe rhinophyma, dense telangiectasia (score 3, severe), or plaque-like
 facial edema.

 3. History of hypersensitivity or allergy to minocycline, any other tetracycline, or of
 any other component of the formulation.

 4. Active ocular rosacea (eg, conjunctivitis, blepharitis, or keratitis) of sufficient
 severity to require topical or systemic antibiotics.